| Patent application number | Description | Published |
|---|
| 20090317799 | Variants at chr8q24.21 confer risk of cancer - A locus on chromosome 8q24.21 has been demonstrated to play a major role in particular forms of cancer. It has been discovered that certain markers and haplotypes are indicative of a susceptibility to particular cancers. Diagnostic applications for identifying susceptibilty to cancer are described. | 12-24-2009 |
| 20100041037 | GENETIC VARIANTS CONTRIBUTING TO RISK OF PROSTATE CANCER - The present invention is characterised by certain genetic variants being susceptibility variants for prostate cancer. The invention relates to methods of determining increased susceptibility to prostate cancer, as well as methods of determining decreased susceptibility to prostate cancer, using such variants. The invention further relates to kits for determining a susceptibility to prostate cancer. | 02-18-2010 |
| 20110020320 | Genetic Variants Contributing to Risk of Prostate Cancer - It has been discovered that certain genetic markers are associated with risk of prostate cancer. The invention describes diagnostic applications for determining a susceptibilty to prostate cancer using such markers, including methods, uses, kits, and computer applications. | 01-27-2011 |
| 20110053281 | Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition - It has been discovered that certain polymorphic markers on chromosome 6 and chromosome 11 are indicative of a susceptibility to prostate cancer and colon cancer. The invention describes diagnostic applications for determining a susceptibility to cancer using such markers, as well as kits for use in such applications. | 03-03-2011 |
| 20110230366 | Genetic Variants Useful for Risk Assessment of Thyroid Cancer - The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including determining increased susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention. | 09-22-2011 |
| 20110287946 | Genetic Variants Useful for Risk Assessment of Thyroid Cancer - The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including methods of determining susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention. | 11-24-2011 |
| Patent application number | Description | Published |
|---|
| 20090054740 | METHOD AND APPARATUS OF CONSTRUCTING AND USING A REFERENCE TOOL TO GENERATE A DISCRIMINATORY SIGNAL FOR INDICATING A MEDICAL CONDITION OF A SUBJECT - This invention relates to constructing a reference tool and using the reference tool for distinguishing between a medical condition of a subject and a reference subject. This tool may be considered as a reference “map” consisting of one or several numbers of reference groups, where the subjects within the same groups share one or more common characteristics, e.g. age, sex, medical condition, etc. The present invention therefore relates to seeing whether a subject to be diagnosed falls within one or more of said groups simply by comparing processed biological data collected from the subject with the reference “map”. | 02-26-2009 |
| 20090220429 | METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS - This invention relates to a method and a system for generating a discriminatory signal for a neurological condition, where at least one probe compound that has a neurophysiologic effect is provided. Biosignal data are obtained from a subject based on biosignal measurements obtained from biosignal measuring device adapted for placement on a subject, wherein said biosignal data are obtained posterior to the administering of said probe compound to the subject. Analogous biosignal reference data are provided for reference subjects in at least one reference group posterior to the administering of the probe compound, wherein the reference data are utilized for defining reference features having common characteristics between the reference subjects in the at least one reference group, wherein the reference data are processed for defining reference posterior probability vectors for each respective reference subject, wherein each respective posterior probability vector comprises particular feature or a feature combination elements with probability values associated to said elements, the posterior probability vectors resulting in a distribution of said features or feature combinations for said reference subjects. Subsequently, the biosignal data obtained from the subject are used for calculating analogues posterior probability vector for said subject. The discriminatory signal is then generated based on comparison between said posterior probability vector for said subject and the distribution of said features or feature combinations. | 09-03-2009 |
| 20100168533 | SYSTEM AND A METHOD FOR GENERATING A QUANTITATIVE MEASURE REFLECTING THE SEVERITY OF A MEDICAL CONDITION - This invention relates to a method and a system for generating a quantitative measure reflecting the severity of a medical condition. A receiver unit receives biosignal data collected from a population of patients having varying degrees of the medical condition. A processor uses the biosignal data for determining reference feature values for each respective patient within the population, where the determining being made in accordance to a pre-defined set of reference features. The processor then assigns each respective patient within the population of patients with a reference feature vector having as vector elements the reference feature values associated with the patient. The processor also uses the reference feature vectors of the patients as input in determining combinations of features describing the variance in the data, where the size of the combinations is an indicator for the severity of the medical condition. This invention further relates to a method and a system for using the quantitative measure for determining a success indicator for a probe compound by implementing the quantitative measure, where a receiver unit receives biosignal data collected from a test subject posterior to administering the probe compound to the test subject, and a processor determines an analogous feature vector as determined for the population of patients. Finally, the processor determines the scalar product between the feature vector determined for the test subject and the combinations of features describing the variance in the data. This scalar product is the success indicator telling how successful the probe compound is. | 07-01-2010 |
